denosumab
Selected indexed studies
- Prevention and Management of Denosumab Discontinuation Rebound Fractures. (Endocrinol Metab Clin North Am, 2024) [PMID:39448137]
- Denosumab discontinuation in the clinic: implications of rebound bone turnover and emerging strategies to prevent bone loss and fractures. (J Bone Miner Res, 2025) [PMID:40057981]
- Stopping Denosumab. (Curr Osteoporos Rep, 2019) [PMID:30659428]
_Worker-drafted node — pending editorial review._
Connections
denosumab is a side effect of
Sources
- Prevention and Management of Denosumab Discontinuation Rebound Fractures. (2024) pubmed
- Denosumab discontinuation in the clinic: implications of rebound bone turnover and emerging strategies to prevent bone loss and fractures. (2025) pubmed
- Stopping Denosumab. (2019) pubmed
- Denosumab for osteoporosis treatment: when, how, for whom, and for how long. A pragmatical approach. (2025) pubmed
- Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. (2015) pubmed
- Denosumab vs. bisphosphonates in primary osteoporosis: a meta-analysis of comparative safety in randomized controlled trials. (2024) pubmed
- Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS. (2017) pubmed
- The Clinical Effectiveness of Denosumab (Prolia®) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis. (2023) pubmed
- Denosumab in elderly osteoporotic patients. A narrative review. (2023) pubmed
- Long-Term Efficacy and Safety of Denosumab: Insights beyond 10 Years of Use. (2025) pubmed